8-K: ESSA Pharma Corrects Due Bill Period for Capital Distribution

ESSA Pharma Inc. announced a correction to the due bill trading period for its previously announced US$80 million capital distribution, clarifying that shares traded ex-dividend as of August 25, 2025.

Summary

• ESSA Pharma Inc. issued a press release on August 25, 2025, to correct an error in a previous announcement regarding the due bill trading period for its US$80,000,000 capital distribution.
• The initial press release on August 14, 2025, inadvertently stated the Due Bill Period as August 19, 2025, through August 25, 2025.
• The correct Due Bill Period was in fact August 19, 2025, through August 22, 2025.
• The capital distribution, amounting to approximately US$1.6910318 per Common Share, was paid to shareholders on August 22, 2025.
• As a result of the correction, Common Shares did not trade with due bills on August 25, 2025, and instead began trading on an ex-dividend basis as of that date.
• This distribution is part of the company's discontinuance and winding-up of its business, following a transaction with XenoTherapeutics, Inc.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While an error was made, it was promptly corrected, providing clarity to shareholders regarding the capital distribution. The distribution itself is a positive event for shareholders in the context of the company winding up.

Positives

• The company promptly corrected an administrative error, ensuring clarity for shareholders regarding the trading of shares post-distribution.
• The capital distribution of US$80,000,000 (approximately US$1.6910318 per share) has been successfully paid to shareholders on August 22, 2025.

Negatives

• An initial error in the press release regarding the due bill trading period caused temporary confusion for shareholders.

Risks

• Risks associated with the proposed timing and completion of the Transaction with XenoTherapeutics, Inc.
• Uncertainty regarding the timing and receipt of securityholder, regulatory, and court approvals for the Transaction.
• Potential for the date of the Special Meeting to change.
• Risk of potential litigation relating to the Transaction that could be instituted by or against ESSA, Xeno, XOMA Royalty Corporation, or their respective directors or officers.
• Disruptions from the Transaction could harm ESSA's business, including current plans and operations.
• Challenges in retaining and hiring key personnel during the Transaction process.
• Potential adverse reactions or changes to business relationships resulting from the announcement or completion of the Transaction.
• Continued availability of capital and financing, and rating agency actions.
• Legislative, regulatory, and economic developments affecting ESSA's business.
• Accuracy of ESSA's financial projections.
• General business, market, and economic conditions.
• Restrictions during the pendency of the Transaction may impact ESSA's ability to pursue certain business opportunities or strategic transactions.
• Unpredictability and severity of catastrophic events, including acts of terrorism, pandemics, outbreaks of war or hostilities.
• Significant transaction costs associated with the Transaction.
• The possibility that the Transaction may be more expensive to complete than anticipated due to unexpected factors or events.
• Competitive responses to the Transaction.
• General business risks and uncertainties as detailed in ESSA's Annual Report on Form 10-K dated December 17, 2024, and the definitive Proxy Statement filed August 11, 2025.

Future Outlook

The company's future outlook is primarily focused on the completion of the Transaction with XenoTherapeutics, Inc., which involves the acquisition of all outstanding Common Shares and the discontinuance and winding-up of ESSA's business. The timing and receipt of necessary approvals, potential litigation, and the ability to manage business disruptions and retain key personnel during this transition are key forward-looking considerations. The company cautions that actual results may differ materially from expectations due to various medical, scientific, business, economic, competitive, regulatory, political, and social uncertainties.

Management Comments

• Shareholders should be advised that the Distribution was paid to Shareholders on August 22, 2025, and as a result Common Shares did not trade with due bills on August 25, 2025 and instead began trading on an ex-dividend basis as of such date.

Industry Context

This announcement is specific to ESSA Pharma's ongoing process of winding up its business and distributing capital to shareholders as part of its acquisition by XenoTherapeutics, Inc. While the company was previously focused on prostate cancer therapies, this filing primarily addresses administrative details related to its corporate dissolution rather than industry-specific drug development or market trends. The transaction itself reflects a strategic shift for ESSA Pharma out of its previous core business.

Comparison to Industry Standards

• This filing concerns an administrative correction related to a capital distribution during a company winding-up process.
• It does not contain performance metrics or operational results that can be directly compared to industry standards, comparable companies, or projects in the biotechnology or pharmaceutical sector.
• The focus is on the accurate execution of a corporate transaction rather than business performance.

Legal Proceedings

• Potential litigation relating to the Transaction that could be instituted by or against ESSA, Xeno, XOMA Royalty Corporation, or their respective directors or officers.

Stakeholder Impact

• Shareholders: Directly impacted by the capital distribution of US$1.6910318 per share and the clarification of the ex-dividend trading date. They are urged to read the Proxy Statement for full details on the Transaction.
• Employees: Risk of impact on ability to retain and hire key personnel due to disruptions from the Transaction.
• Business Relationships: Potential adverse reactions or changes to business relationships resulting from the announcement or completion of the Transaction.

Next Steps

• Completion of the Transaction with XenoTherapeutics, Inc., including obtaining required securityholder, regulatory, and court approvals.
• Potential Special Meeting related to the Transaction.
• Further filings with the SEC regarding the proposed Transaction.

Key Dates

Recommendation

The filing primarily concerns an administrative correction regarding a capital distribution as part of the company's winding-up process. The distribution has already been paid, and the company is in the process of being acquired. There are no new operational or financial performance updates that would warrant a 'buy' or 'sell' recommendation based solely on this filing. Investors who held shares through the distribution have received their capital, and the remaining shares are tied to the ongoing acquisition process. A 'hold' reflects the current transitional state of the company.

Keywords

ESSA Pharma, EPIX, Capital Distribution, Due Bill Period, Ex-Dividend Date, SEC Filing, 8-K, XenoTherapeutics, Winding-up, Shareholder Distribution, Nasdaq, Biotechnology, Prostate Cancer